• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma

by MM360 Staff | Jun 26, 2025 | Myeloma News

Source: Pharmacy Times articles Data from a phase 1b study showed significantly reduced toxicity compared with conventional oral dosing. Read More

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

by MM360 Staff | Jun 25, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Pharmacists Reimagine Myeloma Care With Insights from ASCO

by MM360 Staff | Jun 25, 2025 | Myeloma News

Source: Pharmacy Times articles Gabe Hinojosa, PharmD, BCOP, shares key data for pharmacists from the 2025 American Society of Clinical Oncology Annual Meeting. Read More

A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)

by MM360 Staff | Jun 17, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma

by MM360 Staff | Jun 17, 2025 | Myeloma News

Source: Pharmacy Times articles Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial. Read More

Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

by MM360 Staff | Jun 10, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Future Perspectives in Multiple Myeloma
  • Patients and Caregivers Aim to Raise Funds for Myeloma Research
  • GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
  • Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
  • Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
  • Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
  • Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact
  • SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
  • Multiple Myeloma: A Modern Look at an Ancient Disease and 2025’s Therapeutic Breakthroughs
  • Can Cilta-Cel Redefine Outcomes in Multiple Myeloma?
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT